Physicians > Dr. Cosgriff, M.D.

THOMAS M. COSGRIFF, M.D.
CURRICULUM VITAE

Crescent City Research Consortium, LLC

1111 Medical Center Blvd.. Ste. N701 Marrero, LA 70072

 

Date of Birth:  June 5, 1945; Minneapolis

 

Education:

BA, cum laude, University of Minnesota, Minnesota  1967

BS, University of Minnesota, Minnesota 1970

MD, University of Minnesota, Minnesota 1970

Internship (Internal Medicine), SUNY at Buffalo, New York 1970-71

Residency (Internal Medicine), Brooke Army Medical Center, Houston, Texas 1973-75

Fellowship (Hematology-Oncology), University of Utah, Salt Lake City, Utah 1976-78

 

Medical Statistics, National Institutes of Health, 1979, 1980

Immunohematology and Blood Transfusion, National Institutes of Health, 1981

Mechanics of IND’s and NDA’s, Center for Professional Advancement, 1982

Good Laboratory Practice, Center for Professional Advancement, 1985

Hematopathology Annual Course, Armed Forces Institute of Pathology, 1985

Education in Palliative and End-of-life Care, 2004

Good Clinical Practice, Aureus Research Consultants, 2005

 

Advanced Cardiac Life Support, 1980-2004

Advanced Trauma Life Support, 1992

 

Professional Appointments:

Ward Officer and Chief of Professional Services, US Army Drug Treatment Center, Long Binh, Vietnam, 1971-72

Chief, Outpatient Clinic, McDonald Army Hospital, For Eustis, VA, 1972-73

Chief, Department of Medicine, For Monmouth, NJ, 1975-76

 

Investigator, Division of Experimental Therapeutics, Walter Reed Army Institute of Research (WRAIR), 1978-85

Director, Coagulation Laboratory, United States Army Medical Research Institute of Infectious Diseases

Chief, Department of Clinical Investigation, USAMRIID, 1981-85

Chief, Medical Division, USAMRIID, 1985-89

Attending Physician, Department of Medicine Walter Reed Army Medical Center, 1978-79

 

Clinical Assistant Professor of Medicine, Uniformed Services University of Health Sciences, 1980-87

Clinical Associate Professor of Medicine, Uniformed Services University of Health Sciences, 1988-89

Chief, Hematology-Oncology Service, Fitzsimons Army Medical Center (FAMC), 1989-1993

Associate Clinical Professor of Medicine, University of Colorado Health Sciences Center, 1990-1993

 

Staff Physician, Department of Medicine, East Jefferson Hematology Oncology, Metairie, LA 1994 –Present

Chairman, Division of Palliative Medicine, East Jefferson General Hospital, Metairie, LA 2005-Present

Staff Physician, Jefferson Oncology Clinic, Metairie, LA, 1994-1996

 

Staff Physician, Hematology and Oncology Specialists, LLC, New Orleans, LA 1997 –2012

Chairman, Medical Committee & Research Committee, Hematology and Oncology Specialists, New Orleans, LA, 1997 –2005 (remain a member Member, Executive Committee, Hematology & Oncology Specialists, LLC, New Orleans, LA 2005-

  

Professional Certification:

Internal Medicine (1975) Recertification  (1987, 1997)

Medical Oncology (1997) Recertification (1997, 2006)

Hospice and Palliative Medicine (2005)

 

Research Experience:

Laboratory and Clinical Investigation of Coagulation Abnormalities, University of Utah, 1976-78

Laboratory and Clinical Investigation of Hemostatic Derangement Produces by Infectious and Toxic Agents, USAMRIID, 1978-89

Investigator, Clinical Drug Studies, WRAIR and USAMRIID, 1978-89

Investigator, Clinical Studies, USAMRIID, 1985-89

Research Adviser, National Research Council Associateship Program, 1985-89

Principal Investigator, FAMC, Southwest Oncology Group Clinical Trials, 1990-1993

Principal Investigator, Clinical Trials, Hematology and Oncology Specialists, New Orleans, LA 1997 -

 

Military Service

United States Army Medical Corps 1971-1976, 1978-1993

Retired with rank of Colonel 1993

 

Awards and Honors:

Civilian

Phi Beta Kappa, 1967

Karl Wilheml Stenstrom Student Award for Research in Radiation

Biology, University of Minnesota Medical School, 1970

Fellow, American College of Physicians, 1984

American Cancer Society Spirit Award, 2005

 

Military

Vietnam Service Medal

Republic of Vietnam Campaign Medial

Bronze Star for Meritorious Service

Army Commendation Medal

Meritorious Service Medal

Legion of Merit

Award of the Professional “A” designator by the Surgeon General of the Army, 1988

Commander’s Award, USAMRIID

 

Memberships:

American Academy of Hospice and Palliative Medicine

American Association for the Advancement of Science

American College of Physicians

American Society of Clinical Oncology

American Society of Hematology

International Society on Thrombosis and Haemostatsis

  

PUBLICATIONS

 

1.                   Cosgriff TM.  The metobolic effects of the periwinkle alkaloid vinblastine.  Minn Med 1986; 51:977-982

 

2.                   Cosgriff TM.  Causation as it relates to cancer theory.  Minn Med 1968; 51:983-988

 

3.                   Cosgrff TM.  The effect of vinblastine on compensatory renal growth.  Growth 1970:  34:187-196

 

4.                   Cosgriff TM. Internal and external elements in a community health curriculum.  The New Physician 1970:  19:46-47

 

5.                   Cosgriff TM. Anisocoria in heoin withdrawal.  Arch Neurol 1973;29:200-201

 

6.                   Cosgriff TM, and Arnold WJ.  Digital vasospasm and infarction associated with hepatitis B antigenemia.  JAMA 1976; 245:1362-1363

 

7.                   Cosgriff TM, Olin DB, and Nash DA, Jr.;  Hyporeninemic hypoaldosteronism—case report and observation of dissociated renin and erythropoietin activity.  J Chron Dis 1978; 31:195-200

 

8.                   Ririe DG, Cosgriff TM, and Martin B.  Central retinal vein occlusion in a patient with familial antithrombin III deficiency: case report.  Ann Ophthalmol 1979; 11:1844-1845

 

9.                   Kitahara M, Cosgriff TM, and Eyre HJ.  Sideroblastic anemia as a preleukemic event in patients treated for Hodgkin’s Disease.  Ann Intern Med  1979;  92:625-627

 

10.                Cosgriff TM. Doxorubicin and ventricular arrhythmia.  Ann Intern Med 1980; 92:434-435 (letter)

 

11.                Cosgriff TM, and Martin B.  Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis.  Arth Rheum 1981; 24:94-96

 

12.                Cosgriff TM and McCloskey DW.  Hodgkin disease as the terminal malignancy in Richter syndrome.  Med Ped Oncol 1981; 9:265-272

 

13.                Chen DS, Cosgriff TM, and Kitahara M.  Long-term survival in Wiskott-Aldrich syndrome:  case report and literature review. Am J Med Sci 1981; 282:85-90

 

14.                Cosgriff TM, Boudreau EF, Pamplin CL, Doberstyn EB, Desjardins RA, and Canfield CJ.  Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171, 669). Am J Trop Med Hyg 1982; 21:1075-1079

 

15.                Cosgriff TM, Hodgson LA, and West JV.  The antithrombin III content of blood collected with and without heparin.  Vox Sang 1983: 44:98-101

 

16.                Cosgriff TM, Bishop DT, Hershgold EJ, Skolnick MH, Martin BA, Baty BJ, and Carlson KS.  Familial antithrombin III deficiency:  its natural history, genetics, diagnosis and treatment.  Medicine 1983; 62:209-220

 

17.                Cosgriff TM, Hershgold EJ, Martin BA, and Carlson KS.  False assignment of familial antithrombin III deficiency with the von Kaulla assay.  Am J Clin Pathol 1983; 80:697-699

 

18.                Cosgriff TM.  Blood screening for hepatitis in induced malaria.  Am J Trop Med Hyg 1983;  32:908-909 (letter)

 

 

19.                Canonico PG, Kastello MD, Cosgriff TM, Donovan JC, Ross PE, Spears CT, and Stephen EL.  Hematological and bone marrow effects of ribavirin in rhesus monkeys.  Toxical Appl Pharmacol 1984; 74:163-172

 

20.                Cosgriff TM, Boudreau EF, Pamplin CL, Berman JD, Shmuklarsky MJ, and Canfield CJ.  Evaluation of the 4-pyridinemethanol WR 180, 409 in the treatment of induced Plasmodium falciparum infections in healthy non-immune subjects.  Am J Trop Med Hyg 1984;  33:767-771

 

21.                Cosgriff TM, Hodgson LA, Canonico PG, White JD, Kastello MD, Donovan JC, and Ross PE.  Morphological alterations in blood and bone marrow of ribavirin-treated monkeys.  Acta Haematol 1984; 72-195-200

 

22.                Cosgriff TM, Bunner DP, Wannemacher RW Jr, Hodgson LA, and Dinterman RE.  The hemostatic derangement produced by T-2 toxin in guinea pigs.  Toxical Appl Pharmacol 1984; 76:454-463

 

23.                Cosgriff TM, Pamplin CL, Canfield CJ.  Mefloquine failure in a case of falciparum malaria induced with a multi-drug-resistant isolate in a non immune subject.  Am J Trop Med Hyg 1985; 34:692-693

 

24.                Brunner, DL, Wanner RW Jr, Neufeld HA, Hassler CR, Parker GW, Cosgriff TM, and Dinterman RE.  Pathophysiology of acute T-2 intoxication in the cynomolgus monkey and rat models.  In:  Lacey J, ed.  Trichothecene and Other Mycotoxins.  New York: John Wiley and Sons;  1985:411-421

 

25.                Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, Quakyi IA, Trosper JH, and Hockmeyer WT.  Malaria transmitted to man by mosquitos infected from cultured Plasmodium falciparum.  Am J Trop Med Hyg 1986; 35:66-68

 

26.                Cosgriff TM, Bunner DL, Wannemacher RW Jr, Hodgson LA, and Dinterman RE.  The hemostatic derangement produced by T-2 toxin in cynomolgus monkeys.  Toxical Appl Pharmacol 1986; 82:532-539

 

27.                Bunner DL, Wannemacher RW, Parker GW, Neufeld HA, Pace JG, Thompson W, Cosgriff TM, and Hassler CR.  Acute trichothecene intoxication in animals.  Proceedings of the VI International Conference on the Mycoses.  PAHO Scientific Publication No. 478; 1986:47-56

 

28.                Cosgriff TM, Jahrling PB, Chen JP, Hodgson LA, Lewis RM, Green DE, and Smith JI.  Studies of the coagulation system in arenaviral hemarrhagic fever:  experimental infection of strain 13 guinea pigs with Pichinde virus.  Am J Trop Med Hyg 1987; 36:424-431

 

29.                Lewis RM, Cosgriff TM, Peters CJ, and Morrill JC.  Differentiation of a human moncyte cell line associated with increased production of Rift Valley fever virus by infected cells.  J Med Virol 1987; 23:207-215

 

30.                Yuan GH, Guang MY, Wu ZO, Zhou WH, Zhang TM, Liu XM, Huggins JW, Cosgriff TM, and Smith JI.  Observations on dynamic change of creatinine clearance rate (ccr) in different types of epidemic hemorrhagic fever with renal syndrome (EHRS).  Chinese journal Internal Medicine 1987; 26:458-460

 

31.                Zhang TM, Huggins JW, Zheng ZM, Cosgriff TM, Yang, ZQ, Smith JI, Jiang WL, Hsiang CM, Hang CZ, Wu ZO, Guang MY, Yuan GH, Hu JJ, Zhou WH, Niu CS, and Zhang TH.  Clinical observations on ribavirin therapy in early phase patients with epidemic hemarrhagic fever.  Chinese pharmaceutical bulletin 1987: 22:246-248

 

32.                Wu ZO, Guang MY, Yuan GH, Hang CZ, Huang QT, Wang JZ, Pang LK, Hu JJ, Zhou WH, Niu CS, Zhang TH, Zhang TM, Huggins JW, Cosgriff TM, and Smith JI.  Ribavirin in the treatment of early stage epidemic hemarrhagic fever.  Acta Acadamiae Medicinae Hubei 1987; 8:140-144

 

33.                Xiao SY, Zhu BL, Zhang TM, Zheng ZM, Hsiang CM, Meegan JM, LeDuc JW, Huggins JW, Cosgriff TM, and Smith JI.  Effect of ribavirin on specific humoral immune responses in patients with hemorrhagic fever with renal syndrome (HFRS).  Chinese Journal Virology 1987; 3:243-247

 

34.                Xiao SY, Zhu BL, Zhang TM, Zheng ZM, Hsiang CM, Meegan JM, LeDuc JW, Huggins JW, Cosgriff TM, and Smith JI.  Effect of ribavirin on serum IgG and IgM response in patients with hemorrhagic fever with renal syndrome (HFRS).  Chinese Journal of Virology 1987; 3:243-247

 

35.                Xiang CM, Guang MY, Wang JN, Zheng ZM, Wu ZO, Ge ZQ, Zhang TM, Yuan GH, Gui XE, Huggins JW, Cosgriff TM, Smith JI, LeDuc JW, and Meegan JM.  Study of antiviral-specific therapy of epidemic hemorrhagic fever with ribavirin.  Chinese Journal Experimental Clinical Virology 1988; 2:47-52

 

36.                Lewis RM, Cosgriff TM, Griffin BY, Rhoderick J, and Jahrling PB.  Immune serum increases arenavirus replication in monocytes. J Gen Virol 1988; 69:1735-1739

 

37.                Zhang TM, Xiang JM, Niu CS, Zhou WH, Zhang TH, Huggins JW, Cosgriff TM, Smith JI.  Effects of ribavirin on white blood cells and platelets in patients with epidemic hemorrhagic fever.  Chinese Journal Immunology 1988; 4:287-289

 

38.                Zhang TM, Huggins JW, Yang ZQ, Cosgriff TM, Zhang MY, Smith JI, Zheng ZM, LeDuc JW, Hsiang CM, and Meegan JM.  Analysis of antigenic differences among 40 hemorrhagic fever with renal syndrome (HFRS) virus strains isolated from Hubei by monoclonal antibody.  Acta Acadamiae Hubei 1988; 9:307-308

 

39.                Cosgriff TM and Lewis RM.  Introduction and summary:  International Symposium on Hemostatic Impairment Associated with Hemorrhagic Fever Viruses.  Rev Infect Dis 1989; 11 (Suppl 4): S669-S671

 

40.                Cosgriff TM. Viruses and hemostasis.  Rev Infect Dis 1989; 11 (Suppl 4):S672-S688

 

41.                Lewis RM, Morrill JC, Jahrling PB, and Cosgriff TM.  Replication of viral hemorrhagic fever viruses in monocytic cells. Rev Infect Dis 1989; 11 (Suppl 4): S736-S742

 

42.                Cosgriff TM, Morrill JC, Jennings GB, Hodgson LA, Slayter MV, Gibbs PH, and Peters CJ.  Hemostatic derangement produced by Rift Valley fever virus in rhesus monkeys. Rev Infect Dis 1989;  11(Suppl 4): S807-S814

 

43.                Morrill J, Jennings G, Cosgriff TM, Gibbs P, and Peters CJ.  Prevention of Rift Valley Fever in rhesus monkeys with interferon-x. Rev Infect Dis 1989; 11 (Suppl 4) : S815-S825

 

44.                Fan WF, Yu S, and Cosgriff TM.  The reemergence of dengue in China.  Rev Infect Dis 1989; 11 (Suppl 4): S847-S853

 

45.                Guang MY, Liu GZ, and Cosgriff TM. Hemorrage in hemorrhagic fever renal syndrome in China. Rev Infect Dis 1989; 11 (Suppl 4): S884-S890

 

46.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, Smith JI, Niu CS, Zhou WH, and Zhang TH.  Observations on hematological changes in epidemic hemorrhagic fever.  Acta Acadamiae Medicinae Hubei 1989; 10:197-200

 

47.                Cosgriff TM. Hemorrhagic fever with renal syndrome:  Four decades of research.  Ann Intern Med 1989;  110:313-316

 

 

 

 

48.                Yang ZQ, Zhang TM, Zhang MY, Hu ZJ, Zheng ZM, Qu CF, Chu BL, Hsiang CM, Huggins JW, Cosgriff TM, and Smith JI.  Study of viremia during the febrile phase in patients with epidemic hemorrhagic fever and its relation to disease manifestations. National Medical Journal of China 1990; 70:15-18

 

49.                Yuan GH, Huggins JW, Zhang JR, Cosgriff TM, Guang MY, Smith JI, Wang SJ, and Wu ZO:  Calculation of normal values for creatinine clearance from study of 251 healthy persons.  Chinese Journal Internal Medicine 1990; 29:227-228

 

50.                Morrill JC, Jennings GB, Johnson AJ, Cosgriff TM, Gibbs PH, and Peters CJ.  Pathogenesis of Rift Valley fever in rhesus monkeys:  role of interferon response.  Arch Virol  1990; 110:195-212

 

51.                Xiang LB, Zhang ZY, Chen JM, Xiang JM, Cosgriff TM.  Epidemic hemorrhagic fever: the mechanism of coagulation and fibrinolysis derangment.  Chin Med J 1990; 103:391-395

 

52.                Gordon DM, Cosgriff TM, Schneider I, Wasserman GF, Majarin WR, Hollingdale MR, and Chulay JD.  Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine.  Am J Trop Med Hyg 1990; 42:527-531

 

53.                Cosgriff TM.  Pulmonary edema in falciparum malaria:  slaying the dragon of volume overload.  Chest 1990; 98:10-12 (editorial)

 

54.                Yang ZQ, Zhang TM, Zhang MV, Zheng ZM, Hu ZJ, Qu CF, Xiang JM, Huggins JW, Cosgriff TM, and Smith JI.  Interruption study of viremia in patients with hemarrhagic fever with renal syndrome in the febrile phase.  Chinese Medical Journal 1991; 104: 149-153

 

55.                Cosgriff TM.  Mechanisms of disease in hantavirus infection:  the pathophysiology of hemorrhagic fever with renal syndrome.  Rev Infect Dis 1991; 13: 97-107

 

56.                Lewis RM, Lee HW, See AF, Parrish DB, Moon JS, Kim DJ, and Cosgriff TM.  Changes in populations of immune effector cells during the course of haemorrhaic fever with renal syndrome. Trans Roy Soc Trop Med Hyg 1991; 85:282-286

 

57.                Cosgriff TM, Lee HW, See AF, Parrish DB, Moon JS, Kim DJ, and Lewis RM. Platelet dysfunction contributes to the haemostatic defect in haemorrhagic fever with renal syndrome.  Trans Roy Soc Trop Med Hyg 1991; 85:660-663

 

58.                Cosgriff TM, and Lewis RM.  Mechanisms of disease in hemorrhagic fever with renal syndrome.  Kidney Int 1991: 40(Suppl 35): S72-S79

 

59.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, WuZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Oland DD, Gui XE, Yuan GH, and Zhang TM.  Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome.  J Infect Dis 1991; 164:1119-1127

 

60.                Veloso D, Smith JI, Denny S., and Cosgriff TM.  Structure, kinetics, and function of human and rhesus plasma prekallikreins are similar.  Thromb Haemostas 1992; 68:526-533

 

61.                Yuan J, Huggins JW, Guang MY, Cosgriff TM, and Smith JI.  Rapid calculation of creatinine clearance rate in normal subjects and in patients with epidemic hemorrhagic fever.  Chines Journal Internal Medicine 1992; 31:701-704

 

62.                Zhang TM, Huggins JW, Yang ZQ, Cosgriff TM, Zhang MY, Smith JI, Hu ZJ, and Hsiang CM.  Analysis of viremia and clinical findings in patients with epidemic hemorrhagic fever. Chinese Medical Journal ( in press)

 

63.                Zhang TM, Yang ZQ, Zhang MY, Hu ZJ, Xiang JM, Huggins JW, Cosgriff TM, and Smith JI.  Early analysis of viremia and clinical tests in patients with epidemic hemorrhagic fever.  Chinese Medical Journal 1993; 106:608-610

 

64.                Lum GH, Cosgriff TM, Byrne R, and Reddy V. Primary T-cell lymphoma of muscle in a patient infected with human immunodeficiency virus.  Amer J Med 1993; 95:545-546

 

65.                Veloso D, Denny S, Cosgriff TM, and Hochstein HD. Differential suspectibility of rhesus monkeys to high doses of endotoxin. J Endotox Res 1995; 2:411-420

 

66.                Cosgriff TM, Black ML, Stein W III. Successful treatment of refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin.  Amer J Hematol 1998; 57:85-86

 

67.                Veloso D, Smith JI, and Cosgriff, TM.  Rhesus differential  susceptibility to endotoxin is not associated with activation of plasma prekllikrein.  Immunopharmacol 1999; 43:265-271

 

68.                Chen JP and Cosgriff, TM.  Hemorrhagic fever virus-induced changes in hemostasis and vascular biology.  Blood Coagul Fibrinolysis 2000; 11:461-483

 

69.                Chong C. Bhatnagar A, Cunningham D, Cosgriff, T, Harper P, Steward W, Birdgewater  J, Moore M, Casssidy J, Coleman R, Coxon F, Redfern C, Jones J, Hawkins R, Northfelt A, Sreedharan S, Valone F, and Carmichael J.  Phase III trial of 5fu and leucovorin plus either 3HI anito-idiotype  monoclonal antibody (Cea Vac) Or placebo in patient with advanced colorectal cancer.  Submitted for Publication.

 

 

ABSTRACTS

 

1.                   Bishop DT, Martin B, Baty B, Cosgriff TM, Hershgold E, and Skolnick M. Linkage of antithrombin III deficiency to Duffy blood group.  Am J Human Genetics 1978; 30:48A

 

2.                   Lui CT, Griffin MJ, Jahrling PB, McNamee GA, Cosgriff TM, and Peters CJ.  Phyiological  responses of strain 13 guinea pigs to Pichinde virus infection.  Fed Proc 1982; 41:1133A

 

3.                   Kastello MD, Cosgriff TM, Canonico PG, Wannarka GL, and Spears CT.  Effect of ribavirin on blood and bone marrow of monkeys.  Proceedings of the Annual Meeting of the American Society of Toxicology, Boston, Massachusetts, March 1982

 

4.                   Cosgriff TM, Boudreau EF, Pamplin CL, and Canfield CJ.  The antimalarial activity of the pyridinemethanol WR 180, 409.  Proceedings of the 2nd International Conference on Malaria and Babesiosis, Annecy, France, September 1983

 

5.                   Johnson ED, Cosgriff TM, and McKee KT, Jr.  Experimental Ebola hemorrhagic fever (EHF) in rhesus macaques.  Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, San Antonio, Texas, December 1983

 

6.                   Cosgriff TM. Hemostatic derangement in T-2 toxicosis. Proceedings of the FASEB Conference on Mycotoxins, Saxtons, River, Vermont, June 1984

 

7.                   Cosgriff TM. New antimalarial drugs under development by the US Army. Proceedings of the XIth International Conference of Tropical Medicine and Malaria, Calgary, Alberta, September 1984

 

8.                   Cosgriff TM, Hodgson LA, Lewis RM, and Driessen JL.  Familial thrombopathy with increased activity of factors V, VII, and VIIIc.  Blood 1984; 64(suppl 1):975A

 

9.                   Lewis RM, Johnson ED, Jahrling PB, Edgell C-J, Cosgriff TM, and Peters CJ.  In vitro infection of endothelial cells by Ebola, Lassa and Marburg viruses.  Proceedings of the Annual Meeting of the American Society of Microbiology, Las Vegas, Nevada, March 1985

 

10.                Johnson ED, McKee KT Jr, Jaax N, Dixon J, Lewis RM, and Cosgriff TM.  Experimental Ebola hemorrhagic fever (EHF): a model for rational therapy. Poceedings of the 4th International Congress on the Impact of Viral Diseases on the Development of the African and Middle East Countries, Rabat, Morocco, April 1985

 

11.                Cosgriff T, Hodgson L, Lewis R, Fair D, and Marlar R.  Familial protein S deficiency associated with increased activity of factors V, VII, and VIIIc, and recurrent thrombosis.  Thromb Haemost 1985; 54:219A

 

12.                Cosgriff T, Jahrling P, Green D, and Hodgson L.  The coagulation system in viral hemorrhagic fever:  Pichinde virus infection of strain 13 guinea pigs.  Thromb Haemost 1985; 54:898A

 

13.                Cosgriff T, Morrill J, Jennings G, Peters C, and Hodgson L. Rift Valley Fever Virus in rhesus virus in rhesus monkeys produces multiple hemostatic abnormalities which are prevented by a-interferon.  Throm Haemost 1985;54:907A

 

14.                Lewis RM, Hodgson LA, and Cosgriff TM. T-2 effects on tissue factor production by human monocytes and U937 cells.  Thromb Haemost 1985; 54:1174A

 

15.                Johnson ED, McKee KT Jr, Jaax N, Dixon S, Lewis R, and Cosgriff T. Filovirus infections of rhesus macaques. Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami, Florida, November 1985

 

16.                Milhous WK, Gerena L, and Cosgriff TM.  In vitro induction of resistance to WR 180, 409 (Enpiroline) in a cloned isolate of Plasmodium falciparum.  Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami, Florida, November 1985

 

17.                Cosgriff TM. In vivo and in vitro effects of T-2 toxin on platelets.  Proceedings of the FASEB Conference on Trichothecene Mycotoxins, Copper Mountain,  Colorado, July 1986

 

18.                Huggins JW, Hsiang CM, Cosgriff TM, Wu ZO, Meegan JM, LeDuc JW, Zheng ZM, Smith JI, Ge XQ, Guang MY, Wang QN, Zhang TM, Yuan GH, and Gui XE. Double-blind, placebo-controlled clinical trial of ribavirin therapeutic efficacy in the treatment of epidemic hemorrhagic fever: open phase for dose setting.  Proceedings of the IXth International Congress of Infectious and Parasitic Disease, Munich, Federal Republic of Germany, July 1986

 

19.                Cosgriff, TM. Viruses and hemostasis. Proceedings of the International Symposium on Hemostatic Impairment Associated with Hemorrhagic Fever Viruses, Leesburg, Virginia, May 1987

 

20.                Guang MY, Liu GZ, and Cosgriff TM.  Hemorrhage in hemorrhagic fever with renal syndrom in China.  Proceedings of the International Symposium on Hemostatic Impairment Associated with Hemorrhagic Fever Viruses, Leesburg, Virginia, May, 1987

 

21.                Cosgriff TM, Morrill JC, Jennings GB, Hodgson LA, Slayter MV, Gibbs PH, and Peters CJ.  The hemostatic derangements produced by Rift Valley fever virus in rhesus monkeys.  Proceedings of the International Symposium on Hemostatic Impairment Associated with Hemorrhagic Fever Viruses, Leesburg, Virginia, May 1987

 

22.                Lewis RM, Morrill JC, Jahrling PB, and Cosgriff TM.  U937 cells as an in vitro model of hemorrhagic fever virus infection.  Proceedings of the International Symposium on Hemostatic Impairment Associated with Hemorrhagic Fever Viruses, Leesburg, Virginia, May 1987

 

23.                Jahrling PB, Liu CT, and Cosgriff TM.  The Pichinde model of arenavirus hemorrhagic disease.  Proceedings of the International Symposium on Hemostatic Impairment Associated with Hemorrhagic Fever Viruses, Leesburg, Virginia, May 1987

 

24.                Hsiang CM, Huggins JW, Guang MY, Cosgriff TM, Zheng ZM, Smith JI, Wu WO, Wang QN, LeDuc JW, Ge XQ, Meegan JM, Gui XE, and Zhang TM.  Effective therapy of epidemic hemorrhagic fever with ribavirin in a double-blind, randomized, controlled trial. II. Improvement in some clinical signs:  hematology, cardiology, nephrology, and immunology.  Proceedings of the 29th International Colloquium on Hantaviruses, Antwerp, Belgium, July 1987

 

25.                Cosgriff TM, Canonico PG, Hodgson L, Parrish D, Chapman T, Huggins JW, Gong ZJ, Xiang LB, and Hsiang CH.  Ribavirin:  studies on the effects of the antiviral drug on platelet function.  Thromb Haemost 1987; 58:1746A

 

26.                Lewis RM, Jahrling PB, Griffin BP, and Cosgriff TM. The effect of hemorrhagic fever virus infection of endothelial cells. Throm Haemost 1987; 58:553A

 

27.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gui XE, Yuan GH and Zhang TM.  Clinical therapeutic efficacy of high dose intravenous ribavirin treatment of hemorrhagic fever with renal syndrome (HFRS): randomized, double-blind, placebocontrolled trial in the Peoples Republic of China.  Proceedings of the VIIth International Congress of Virology, Edmonton, Alberta, August 1987

 

28.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gui XE, Yuan GH, and Zhang TM, and Lee HW.  Intravenous ribavirin therapy of hemorrhagic fever with renal syndrom. Proceedings of the XVIth Pacific Science Conference, Seoul, Korea, August 1987

 

29.                Cosgriff TM, Parrish DB, Jahrling PB, Huggins JW, Lewis RM, and Peters CJ. The original hemorrhagic fever revisited: hemostatic derangement in rhesus monkeys infected with yellow fever virus. Thromb Haemost 1987; 70:369A

 

30.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gui XE, Yuan GH, Zhang TM and Lee HW. Intravenous ribavirin therapy of hemorrhagic fever with renal syndrome (HFRS). Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Los Angeles, California, November 1987

 

31.                Fajfar-Whetstone CJ, Kakoma I, Hansen R, Buese M, Ristic M, and Cosgriff TM. Analysis of Plasmodium falciparum-specific antibodies on sequential serum samples from infected human volunteers, using the immunoflourescent and antibody test, Western immunoblotting and an in vitro neutralization assay.  Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Los Angeles, California, November 1987

 

32.                Jahrling, PB, Peters CJ, Huggins JW, Cosgriff TM, and Monath TP. Ribavirin therapy of yellow fever.  Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Los Angeles, CA, November 1987

 

33.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, Smith JI, Niu CS, Zhou WH, and Zhang TH. Study of the effects of ribavirin on red blood cells in patients with epidemic hemorrhagic fever.  Proceedings of the Second Chinese National Conference on Nucleoside and Nucleotide Drugs, Beijing, Peoples’ Republic of China, December 1987

 

34.                Jahrling PB, Trotter RW, Barrer Oro JG, Lupton HW, Cosgriff TM, Lewis RW, Parrish DB, Smith SB, and Peters CJ. Cross-Protection against Machupo with Candid #1 live, attenuated Junin virus vaccine. III. Post challenge clinical findings.  Proceedings of the 2nd International Conference on the Impact of Viral Diseases on the Development of Latin American Countries and the Caribbean region, Mar del Plata, Argentina, March 1988

 

35.                Hsiang CM, Guang MY, Wang QN, Zheng ZM, Wu ZO, Ge XQ, Zhang TM, Gui XE, Huggins JW, Cosgriff TM, Smith JI, LeDuc JW, and Meegan JM. Effective therapy of epidemic hemorrhagic fever patients with ribavirin: decreased mortality and reversible anemia. Proceedings of the Second International Conference on Antiviral Research, Williamsburg, Virginia, March 1988

 

36.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, Smith JI, and Niu CS. A study of the effects of ribavirin on white blood cells and platelets in patients with epidemic hemorrhagic fever. Proceedings of the 2nd International Conference on Antiviral Research, Williamsburg, Virginia, March 1988

 

37.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gui XE, Yuan GH, Zhang TM, Gibbs PH, and Oland DD. Intravenous ribavirin therapy for hemorrhagic fever with renal syndrome (HFRS). Proceedings for the 2nd International Conference on Antiviral Research, Williamsburg, Virginia, March 1988

 

38.                Hsiang CM, Guang MY, Wang QN, Zheng ZM, Wu ZO, Ge XQ, Zhang TM, Gui XE, Huggins JW, Cosgriff TM, Smith JI, LeDuc JW, and Meegan JM. Effective therapy of epidemic hemorrhagic fever patients with ribavirin: decreased mortality and reversible anemia. Antiviral Research 1988; 9:147A

 

39.                Cosgriff, TM. The pathophysiology of hemorrhagic fever with renal syndrome. Presented at the One Day Symposium on Hemorrhagic Fever with Renal Syndrome, Frederick, Maryland, March, 1988

 

40.                Zhang TM, Huggins JW,  Hsiang CM, Cosgriff TM, Smith JI, and Niu CS. A study of the effects of ribavirin on white blood cells and platelets in patients with epidemic hemorrhagic fever. Antiviral Res 1988; 9:148A

 

41.                Huggins JW, Cosgriff TM, Smith JI, LeDuc JW, Meegan JM, Hsiang CM, Guang MY, Wu ZO, Zhang TM, and Lee HW. Intravenous ribavirin therapy for Korean hemorrhagic fever (Korea) – epidemic hemorrhagic fever (China).  Proceedings of the Annual Meeting of the Society of Armed Forces Medical Laboratory Scientists, Reno, Nevada, April 1988

 

42.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, Niu CS, Smith JI, Zhou WH, and Zhang TH. A study of the effects of ribavirin on white blood cells and platelets in patients with epidemic hemorrhagic fever. Proceedings of the International Symposium on Viral Diseases: Prevention, Strategy, and Therapy, Shanghai, People’s Republic of China, May 1988

 

43.                Xiang LB, Cosgriff TM, and Hsiang CM. Improvement of some hematological parameters in ribavirin-treated epidemic hemorrhagic fever patients in Hubei, China. Antiviral Res 1988; 9:148A

 

44.                Jahrling PB, Trotter RW, Barrera Oro JG, Lupton HW, Cosgriff TM, and Peters CJ. Cross-protection against Machupo with Candid #1 live, attenuated Junin virus vaccine. Proceedings of the 78th Annual Meeting of the American Society for Virology, Austin, Texas, June 1988

 

45.                Cosgriff TM, Hsiang CM, Huggins JW, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gibbs PH, Gui XE, Yuan GH, and Zhang TM. Predictors of fatal outcome in the severe form of hemorrhagic fever with renal syndrom (HFRS). Proceedings of the 1st International Symposium on Hantaviruses and Crimean-Congo Hemorrhagic Fever Virus, Porto Carras, Halkidiki, Greece, September 1988

 

46.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gui XE, Yuan GH, Zhang TM, Gibbs PH, and Oland DD. Treatment of HFRS with high-dose intravenous ribavirin. Proceedings of the 1st International Symposium on Hantaviruses and Crimean – Congo Hemorrhagic Fever virus, Porto Carras, Halkidiki, Greece, September 1988

 

47.                Cosgriff TM, Hsiang CM, Huggins JW, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gibbs PH, Gui XE, Yuan GH, and Zhang TM. Predictors of fatal outcome in epidemic hemorrhagic fever.  Proceedings of the International Symposium on Hemarrhagic Fever with Renal Syndrome, Wuhan, People’s Republic of China, November 1988

 

48.                Yuan GH, Huggins JW, Xiang CM, Cosgriff TM, Guang MY, Smith JI, Cheng LJ, Zhang JR, Hu JJ, Zhang TH, Zhou WH, Niu CS, Liu XM, Wang DF, Xu XF, Song JL, and Leng SX. The effects of ribavirin on serum creatinine clearance rate (Ccr) in patients with EHF.  Proceedings of the International Symposium on Hemorrhagic Fever with Renal Syndrome, Wuhan, People’s Republic of China, November 1988

 

49.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gui XE, Yuan GH, Zhang TM, Gibbs PH, and Oland DD. Ribavirin therapy of HFRS: overall study of the efficacy of high-dose intravenous therapy. Proceedings of the International Symposium on Hemarrhagic Fever with Renal Syndrome, Wuhan, People’s Republic of China, November 1988

 

50.                Zhang TM, Huggins JW, Yang ZQ, Cosgriff TM, Zhang MY, Smith JI, Zheng ZM, LeDuc JW, Hsiang CM, and Meegan JM. Analysis of antigenic differences among 40 hemarrhagic fever with renal syndrome (HFRS) virus strains isolated from Hubei by monoclonal antibody. Proceedings of the International Symposium on Hemarrhagic Fever with Renal Syndrome, Wuhan, People’s Republic of China, November 1988

 

51.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, Smith JI, LeDuc JW, and Meegan JM. Role of the complement system in the pathogenesis of epidemic hemorrhagic fever. Proceedings of the International Symposium on Hemarrhagic Fever with Renal Syndrome, Wuhan, People’s Republic of China, November 1988

 

52.                Xiang LB, Chen JM, Zhang ZY, and Cosgriff TM. Study on mechanisms of hemorrhage, coagulation and fibrinolysis in EHF patients. Proceedings of the International Symposium on Hemarrhagic Fever with Renal Syndrome, Wuhan, People’s Republic of China, November 1988

 

53.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, and Smith JI. The effect of C3 and C4 on the pathogenesis of haemorrhage and renal damage in patients with epidemic haemorrhage fever. Proceedings of the First Asia-Pacific Congress of Medical Virology, Singapore, November 1988

 

54.                Zhang TM, Huggins JW, Yang ZQ, Cosgriff TM, Zhang MY, Smith JI, Zhang ZM, LeDuc JW, Hsiang CM, and Meegan Jm. Analysis of antigenic differences amoung 40 haemorrhagic fever with renal syndrome virus isolates from Hubei using monoclonal antibodies. Proceedings of the First Asia-Pacific Congress of Medical Virology, Singapore, November 1988

 

55.                Lewis RM, Ussery MA, and Cosgriff TM. Immune serum does not enhance infection of endothelial cells with dengue virus. Blood 1988; 72 (Suppl 1): 1113A

 

56.                Popovic NA, Oland DD, and Cosgriff TM. Evaluation of a live, attenuated Venezuelan equine encephalomyelitis vaccine (TC-83). Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, December 1988

 

57.                Egan JE, Cosgriff TM, Wasserman GF, Young JF, Wirtz RA, Schneider I, Hollingdale MR, Chulay JD, and Ballou WR. Immunization of human volunteers with recombinant Plasmodium falciparum sporozoite vaccine, R32NSI81. Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, December 1988

 

58.                Rickman LS, Long G, Oberst RB, Egan JE, Cosgriff TM, Chulay JD, and Hoffman SL. Rapid diagnosis of malaria by acridine orange staining of centrifuged parasites. Proceedings of the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, December 1988

 

59.                Cosgriff TM. The pathophysiology of hemorrhagic fever with renal syndrome. Proceedings of the 1st International Conference on Hemarrhagic Fever with Renal Syndrome, Seoul, Korea, May, 1989

 

60.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZA, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gibbs PG, Gui XE, Yuan GH, Zhang TM, Oland DD, and Lee HW. Chemotherapy of HFRS. Proceedings of the 1st International Conference on Hemarrhagic Fever with Renal Syndrome, Seoul, Korea, May, 1989

 

61.                Lewis RM, Lee HW, See AF, Parrish DB, Moon JS, Kim DJ, and Cosgriff TM. Changes in lymphocyte subpopulations during HFRS. Proceedings of the 1st International Conference on Hemarrhagic Fever with Renal Syndrome, Seoul, Korea, May, 1989

 

62.                Lewis RM, Lee HW, See AF, Parrish DB, Moon JS, Kim DJ, and Cosgriff TM. Platelet aggregation and release in HFRS patients. Proceedings of the 1st International Conference on Hemarrhagic Fever with Renal Syndrome, Seoul, Korea, May, 1989

 

63.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, and Smith JI. Dynamic observation of blood system changes in epidemic hemorrhagic fever. Proceedings of the 1st International Conference on Hemarrhagic Fever with Renal Syndrome, Seoul, Korea, May, 1989

 

64.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM and Smith JI. Detection and clinical significance of creatine phophate kinase isoenzymes in epidemic hemorrhagic fever. Proceedings of the 1st International Conference on Hemarrhagic Fever with Renal Syndrome, Seoul, Korea, May, 1989

 

65.                Zhang TM, Huggins JW, Cosgriff TM, Zhang MY, Smith JI, Zheng ZM, LeDuc JW, Hsiang CM, and Meegan JM. Antigenic analysis of 40 HFRS virus strains from Hubei, China. Virus Information Exchange Newsletter 1989; 6:13A

 

66.                Zhang TM, Hsiang CM, Niu CS, Zhou WH, Zhang TH, Huggins JW, Cosgriff TM, and Smith JI. Effect of ribavirin on white blood cells and platelets in patients with epidemic hemorrhagic fever. Virus Information Exchanges Newsletter 1989; 6:13A

 

67.                Zhang TM, Hsiang CM, Niu CS, Zhou WH, Huggins JW, Cosgriff TM, and Smith JI. Changes in blood composition of patients with epidemic hemorrhagic fever. Virus Information Exchange Newsletter 1989; 6:13A

 

68.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM and Smith JI. Detection and significance of creatine phophate kinase isoenzymes in epidemic hemorrhagic fever. Virus Information Exchange Newsletter 1989; 6:13A

 

69.                Cosgriff TM, Parrish DB, Major MA, Gong ZJ, and Xiang LB. Disseminated intravascular coagulation in hemorrhagic fever with renal syndrome. Thromb Haemost 1989; 62:1163A

 

70.                Lewis RM, Lee HW, See AF, Parrish DB, Moon JK, Kim DJ, and Cosgriff TM. The nature of defective platelet function in patients with hemorrhagic fever with renal syndrome (HFRS). Thromb Haemost 1989; 62:359A

 

71.                Cosgriff TM. Hemorrhagic fever with renal syndrome. Internal Medicine Digest 1989; 7:13-14A

 

72.                Cosgriff TM. Hemorrhagic fever with renal syndrome. Infect Dis Digest 1989; 7:16-18A

 

73.                Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZA, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Gibbs PH, Gui XE, Yuan GH, Zhang TM, Oland DD, and Lee HW. Ribavirin chemotherapy of hemorrhagic fever with renal syndrome (HFRS). Proceedings of the International Symposium on Arboviruses and Arboviral Infections, Moscow, USSR, October 1989

 

74.                Zhang TM, Huggins JW, Yang ZQ, Cosgriff TM, Guang MY, Smith JI, Zheng ZM, LeDuc JW, Hsiang CM, and Meegan JM. The isolation and analysis of HFRS virus from plasma and urine of patients with epidemic hemorrhagic fever. Proceedings of the International Symposium on Arboviruses and Arboviral Infections, Moscow, USSR, October 1989

 

75.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, and Smith JI. Measurement and clinical significance of creatine phosphokinase isoenzymes in epidemic hemorrhagic fever in Wuhan, Hubei Province, Peoples Republic of China. Proceedings of the International Symposium of Arboviruses and Arboviral Infections. Moscow, USSR, October, 1989

 

76.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, and Smith JI. Observations of hematologic changes in epidemic hemorrhagic fever in Wuhan, Hubei Province, Peoples Republic of China. Proceedings of the International Symposium of Arboviruses and Arboviral Infecions. Moscow, USSR, October 1989

 

77.                Cosgriff TM. The pathophysiology of hemorrhagic fever with renal syndrome (HFRS). Proceedings of the International Society of Nephology Satellite Symposium on Virus-Related Renal Disease, Kyung, Korea, July 1990

 

78.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, and Smith JI. Dynamic observations of blood system changes in epidemic hemorrhagic fever. Biological Abstracts 1990; 89:27137A

 

79.                Wang FS, Cosgriff TM, and Bunner DL. Effects of cytokines on the protein C and protein S concentration in supernates from Hep G2 cell culture. Blood 1990; 76 (Suppl 1):442A

 

80.                Cosgriff TM. Mechanisms of disease in Hantavirus infection: Pathophysiology of hemorrhagic fever with renal syndrome. Infect Dis Digest 1991

 

81.                Zhang TM, Huggins JW, Yang ZQ, Cosgriff TM, Zhang MY, Smith JI, and Zhang TH. Relationships between kidney damage, viremia, complement levels, and prognosis in epidemic hemorrhagic fever patients. Virus Information Exchange Letter 1991; 8:121A

 

82.                Zhang TM, Huggins JW, Hsiang CM, Cosgriff TM, Zhou WH, Smith JI, and Hu ZJ. Analysis of viremia and clinical findings in patients with epidemic hemorrhagic fever in the early phase. Proceedings of the Second International Conference on Hemorrhagic Fever with Renal Syndrome, Beijing, People’s Republic of China, October, 1992

 

83.                Yuan GH, Wang SJ, Lin H, Guang MY, Zhang XI, Huggins JW, Cosgriff TM, and Smith JI. Investigation of the relationship between creatinine clearance rate and other renal function indices in HFRS. Proceedings of the second Intenational Conference on Hemorrhagic Fever with Renal Syndrom, Beijing, People’s Republic of China, October, 1992

 

84.                Smith JI, Xing SF, Cosgriff TM, Yi XP, and Huggins JW. Retrospective and prospective controlled study of the gross and microscopic pathology of 18 patients who died of epidemic hemorrhagic fever in Hubei Province, People’s Republic of China. Proceedings of the Annual Meeting of the American Society of Clinical Pathology/College of American Pathologists, Anaheim California, October, 1993

 

85.                Smith JI, Xing SF, Cosgriff TM, Yi XP, Tong ZG, and Huggins JW. Retrospective and prospective controlled study of the immunopathology of 18 patients who died of epidemic hemorrhagic fever in Hubei Province, People’s Republic of China. Proceedings of the Annual Meeting of the Society of Armed Forces Medical Laboratory Scientists, March, 1994

 

86.                Cosgriff TM, Black ML, and Stein W, III. Liposomal doxorubicin produces remissions in severe refractory idiopathic thrombocytopenic purpura. Blood 1997; 90:3078A

 

87.                Veloso D, Smith JI, and Cosgriff TM.  Rhesus differential susceptibility to endotoxin is not associated with prekallikrein activation.  The 15th International Conference on Kinins, Nara, Japan, September, 1998

 

88.                Cosgriff TM, Black ML, and Stein W, III.  Severe refractory idiopathic thrombocytopenic purpura responds to liposomal doxorubicin.  Thromb Haemost 1999; 82:1941A

 

89.                Veloso D, Smith JI, Guynn RW, and Cosgriff TM.  Differentiated and undifferentiated responses or rhesus monkeys to high doses of endotoxin.  Thromb Haemost 1999;82:33A

 

90.                Perez EA, Lambert-Falls R, Deutsch M, Desch C, Justice G, Cosgriff T, Headly D, and Palmieri FM.  Phase II adjuvant trial of concurrent epirubicin/taxan versus sequential epirubicin/cyclosphosphamide followed by taxane for node-positive breast cancer; safety analysis.  25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December, 2002

 

91.                Bhatnagar A, Carmicahel J, Cosgriff T, Harper P, Steward W, Birdgewater J, Moore M, Redfern C, Valone F and Cunningham D.  A Randomized, double-blind, placebo controlled phase III study of monoclonal antibody 3H1 plus 5-fluorouracil (5-FU)/Leucovorin (LV) in state IV colorectal carcinoma. J Clin Oncol 2003; 22:1041A

 

92.              Reid T, Weeks AE, Vakil M, Cosgriff T, Harper H, Yen K, Scislowski P, Scappaticci F, Valone F, and Bhatnagar A.  Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer.  10th World Conference on Lung Cancer, Vancouver, British Columbia, August 12, 2003.

 

93.              Reid T, Weeks AE, Cosgriff T, Harper T, Valone F, Magnuson D, and Bhatnagar A. Dose escalation study of Pivanex (A Histone Deacetylase Inhibitor) in combination with Docetaxel for Advanced Non-Small Cell Lung Cancer. ASCO 40th Annual Meeting, Ernest N. Morial Convention Center, New Orleans, LA, June 5-8, 2004.

 

94.              Boccia RV, Dakhil S, Cosgriff T, Pink C, Butler B. Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer.  Preliminary safety results. J Clin Oncol 2004; 22:

 

95.              Scott J, Dakhil S, Cosgriff T, Pink C, Butler B, Boccia RV, Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer.  J Clin Oncol 2005; 23:3705A

 

96.              Lyons R, Cosgriff T, Modi S, Lintz L, Beach CL, PharmD, and Backstrom J.  Azacitidine (Vidaza) treatment response assessed using three alternative dosing schedules in patients with myelodysplastic syndromes (MDS).  Blood 2005: 106:2517A

 

97.              Dakhil S, Cosgriff T, Headley D, Boccia RV, Badarinath S, Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer.  J Clin Oncol 2006; 25:3557A

 

98.              Anthony S, Lyons R, Cosgriff T, Modi S.  Transfusion independence assessed using three alternative dosing schedules of azacytidine in patient with myelodysplastic syndrome (MDS). J Clin Oncol 2006; 24:6574A

 

99.              Mirtsching B, Chidiac T, Cosgriff T.  First-line treatment of metastic breast cancer with weekly Abraxane (nab-paclitaxel: a 130nm albumin-bound paclitaxel particle: a preliminary analysis of the phase II International Oncology Network ION-04-012 study. J Clin Oncol 2006; 24:10707A

 

100.          Mirtsching BC, Cosgriff T, Chidiac T, Harker G, Keaton M, Min M.  First-line treatment of metastatic breast cancer with weekly Abraxane (an International Oncology Network Study, ION-04-012.) Accepted for presentation at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December, 2006.

 

BOOK REVIEWS

1.                  Seifter EJ, Bell WR. Coagulation Disorders in the Cancer Patient.  Mount Kisco, New York Futura Publishing Co., Mount Kisco, New York: Futura Publishing Co.; 1984.  In Critical Care Medicine 1985; 13:697